Business Wire

Leading Global Battery Expert Kenneth Hoffman to Join Pure Lithium as Special Advisor

21.4.2025 16:52:00 CEST | Business Wire | Press release

Share

Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announces that Kenneth Hoffman (CFA, CIM) will join the company as a Special Advisor, leveraging his vast experience across the battery value chain to advance our drive towards full commercialization.

Mr. Hoffman, who was previously Global Head of Battery Materials at McKinsey, will be a crucial asset for Pure Lithium’s commercialization strategy and development of partnerships. Working directly with Pure Lithium CEO Emilie Bodoin, he will bring a deep understanding of batteries and a unique ability to connect market dynamics with operational decision making that will be invaluable for Pure Lithium.

Pure Lithium Founder and CEO Emilie Bodoin said:
“I feel very privileged to bring Ken aboard at this crucial time in Pure Lithium’s evolution. He is simply one of the leading experts on batteries, forming partnerships and developing successful businesses in energy storage. We are sure that he going to make a major contribution to Pure Lithium as we move toward commercial production of our next-generation lithium metal vanadium battery.”

Mr. Hoffman has spent more than 25 years in investing, managing and directing tens of billions of dollars as a Portfolio Manager, and global Director of Research for various large funds including Millennium Partners and Reservoir Capital. His broad, hands-on experience as an investor and consultant will help Pure Lithium identify and capitalize on business and financial opportunities and bring vast insight to mitigating supply chain risks.

In late 2016, Mr. Hoffman agreed to join McKinsey’s Global Energy & Mining practice (GEM) to lead mining company strategy in gold, copper, nickel, manganese and lithium as well as battery raw material value chains. He has worked on more than 100 due diligences from the analysis of lithium assets to the study of more than a dozen direct lithium extraction technologies.

He is one of the main presenters at metal and mining forums as well as global battery conferences and global media, including an opening keynote at PDAC, The Future Minerals Forum in Riyadh, Fastmarkets events in Asia, North America, Europe and South America, the London Metals Exchange Week conferences in Hong Kong and London and Australia’s AUSIMM general gathering. Mr. Hoffman is a Director of “The Battery Show,” the largest battery event in North America.

About Pure Lithium

Pure Lithium is a disruptive Boston-based lithium metal battery technology company led by its founders, inventor and lithium expert, CEO Emilie Bodoin, and world-renowned battery and metallurgical expert, MIT Emeritus Professor Donald R. Sadoway, as full-time CSO. The Company's novel Brine to Battery™ technology combines metal extraction and anode production, bypassing traditional lithium compound production. The resulting pure lithium metal anode is the core component of our lithium metal vanadium oxide battery, a step-change improvement over today’s lithium-ion technology in cell performance, cost and safety. Additionally, the battery is free of graphite, cobalt, nickel and manganese. For more information, visit www.purelithium.io or email news@purelithium.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250421673825/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye